Skip to content

Assessing brain hemodynamics using Arterial Spin Labeling MRI.

Assessing brain hemodynamics using Arterial Spin Labeling MRI. - A-CO2

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON35194
Enrollment
160
Registered
2011-11-09
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebrovascular disease stroke

Interventions

All volunteers and patients will be exposed to step wise respiratory challenges with a maximum of 4 minutes of end tidal CO2 pressure (= arterial pressure) of 50 mmHg CO2 and minimum O2 level of 100

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: (p. 15 protocol) > 18 year informed consent Intracranial occlusion Extracranial occlusion Extracranial stenosis In stroke patients, MRI scan within one week of symptom onset

Exclusion criteria

Exclusion criteria: (p.15 protocol) Contraindications for MRI (claustrophobia, or standard MRI contraindications such as pacemakers or specific metal objects in or around the body) Unwilling or unable to co-operate with breathing manoeuvres Respiratory or cardiac limitations to breathing at 20L/min Medical contra-indications to limited hypercapnia (known increased intracerebral pressure, metabolic acidosis or alkalosis) Altered consciousness Non compliance with prescribed anti-seizure medication

Design outcomes

Primary

MeasureTime frame
Our objective is to test the feasibility of the application of a CO2-challenge to measure Cerebrovascular Reactivity in healthy subjects and in cerebrovascular diseased patients with Arterial Spin Labeling MRI and to test the feasibility of a Velocity-Selective Spin Labeling sequence to measure the Cerebral Metabolic Rate of Oxygen.

Secondary

MeasureTime frame
To obtain baseline values of these two parameters in a healthy control group and in patients with cerebrovascular disease.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)